Analyses of Efficacy End Points in a Controlled Trial of Interferon-γ1b for Idiopathic Pulmonary Fibrosis
- 1 January 2005
- journal article
- Published by Elsevier BV in Chest
- Vol. 127 (1), 171-177
- https://doi.org/10.1378/chest.127.1.171
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Interferon Gamma-1b for Pulmonary FibrosisNew England Journal of Medicine, 2004
- A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2004
- Idiopathic Pulmonary FibrosisDrugs, 2004
- Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Fibrotic Idiopathic Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Idiopathic Pulmonary Fibrosis: Diagnosis and TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2000
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 1999
- Changes in Pulmonary Function Test Results After 1 Year of Therapy as Predictors of Survival in Patients With Idiopathic Pulmonary FibrosisChest, 1995
- Statistical Problems in the Reporting of Clinical TrialsNew England Journal of Medicine, 1987